Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 6/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 6/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4653470 | 1.00 | FURIN (0.45) | FURINSIRT6SIRT1ERAP2LNPEP | |
| SCHEMBL468887 | 0.85 | SLC6A5 (0.54) | SIRT6SIRT1PAOXSLC6A5F2 | |
| SCHEMBL468889 | 0.85 | SLC6A5 (0.54) | SIRT6SIRT1PAOXSLC6A5F2 | |
| SCHEMBL5494276 | 0.84 | SIRT6 (0.54) | FURINSIRT6SIRT1ERAP2LNPEP | |
| SCHEMBL2387748 | 0.84 | SIRT6 (0.54) | FURINSIRT6SIRT1ERAP2LNPEP | |
| Xylose SCHEMBL22729263 | 0.84 | FURIN (0.37) | FURINSIRT6SIRT1ERAP2LNPEP | |
| SCHEMBL27846711 | 0.83 | ERAP2 (0.43) | SIRT6SIRT1ERAP2LNPEPSLC6A5 | |
| SCHEMBL27846706 | 0.83 | ERAP2 (0.43) | SIRT6SIRT1ERAP2LNPEPSLC6A5 | |
| SCHEMBL5333662 | 0.83 | ERAP2 (0.45) | SIRT6SIRT1ERAP2LNPEPSLC6A5 | |
| Hydrochloric Acid SCHEMBL2122175 | 0.83 | SIRT6 (0.52) | FURINSIRT6SIRT1ERAP2LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0190041-A2 | Stabilized plasminogen activator precursor and method of producing the same | GREEN CROSS CORPORATION (JP) | 1986-08-06 | — | — | EP | claimed |
| JP-57016698-A | — | — | None | — | — | JP | disclosed |
| JP-61176532-A | — | — | None | — | — | JP | disclosed |
| EP-1594492-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGES) | HOPE CITY (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1370256-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGES) | HOPE CITY (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1594492-A4 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGES) | HOPE CITY (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7030133-B2 | Inhibitors of formation of advanced glycation endproducts (AGEs) | CITY OF HOPE (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1594492-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGES) | CITY OF HOPE (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040198795-A1 | Substituted imidazoliums and methods of use therefor | SYNVISTA THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-2004071416-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGES) | CITY OF HOPE (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-1997042175-A1 | SUBSTITUTED IMIDAZOLIUM SALTS AND THEIR USE FOR THE INHIBITION OF PROTEIN AGEING | ALTEON INC. (US) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997035849-A1 | 1,2,4-TRIAZINE DERIVATIVES FOR THE INHIBITION OF PROTEIN GLYCOSYLATION | ALTEON INC. (US) | 1997-10-02 | — | — | WO | disclosed |
| US-5661139-A | FOR INHIBITING GLYCOSYLATION OF PROTEINS TO PREVENT DISCOLORATION OF THE TEETH | ALTEON INC. (US) | 1997-08-26 | — | — | US | disclosed |
| WO-1997023447-A1 | N-ACYLAMINOALKYLHYDRAZINECARBOXIMIDAMIDES | ALTEON INC. (US) | 1997-07-03 | — | — | WO | disclosed |
| WO-1996040622-A1 | BIS-(2-ARYL)HYDRAZONES AS INHIBITORS OF THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0190041-A3 | STABILIZED PLASMINOGEN ACTIVATOR PRECURSOR AND METHOD OF PRODUCING THE SAME | GREEN CROSS CORPORATION (JP) | 1988-09-28 | — | — | EP | disclosed |
| JP-S61176532-A | STABLIZATION OF PLASMINOGEN ACTIVATOR PRECURSOR | GREEN CROSS CORP:THE | 1986-08-08 | — | — | JP | disclosed |
| EP-0190041-A2 | Stabilized plasminogen activator precursor and method of producing the same | GREEN CROSS CORPORATION (JP) | 1986-08-06 | — | — | EP | disclosed |
| EP-0190041-A2 | Stabilized plasminogen activator precursor and method of producing the same | GREEN CROSS CORPORATION (JP) | 1986-08-06 | — | — | EP | disclosed |
| JP-S5716698-A | MEASURING METHOD OF ALPHA2-PLASMIN INHIBITOR | YATORON:KK | 1982-01-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198795-A1 | Substituted imidazoliums and methods of use therefor | AGER, NOTUM, IDE | FURIN 2408/4885SIRT6 716/4885SIRT1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.